HeartBeam (NASDAQ: BEAT) announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio, company leadership, and institutional investors. The funds will be directed toward commercializing HeartBeam's FDA-cleared 12-lead synthesized ECG system, further developing its extended-wear patch and heart attack detection technologies, expanding AI capabilities, and for general corporate purposes.
The offering marks a significant milestone for HeartBeam as it transitions from development to commercial stage. The company's 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis in December 2025, enables cable-free collection of ECG signals from three non-coplanar directions. This platform is designed for portable devices that allow physicians to identify cardiac health trends and acute conditions outside traditional medical facilities.
HeartBeam holds over 20 issued patents related to its technology. The company aims to redefine cardiac health management by providing actionable heart intelligence wherever the patient is located. The $10 million capital infusion is expected to accelerate the rollout of its products and support ongoing innovation in AI-driven cardiac diagnostics.
For more details on the offering, visit https://ibn.fm/9iNYY. Additional updates and news regarding HeartBeam are available in the company's newsroom at https://ibn.fm/BEAT.
